22.53

0.49% -0.11

After Hours: 22.53

Collegium Pharmaceutical Inc (COLL)

Overview News Price History Option Chain Financials Discussions Forecast

Collegium Pharmaceutical Inc stock is traded at $22.53, with a volume of 503.43K. It is down -0.49% in the last 24 hours and down -17.98% over the past month. Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.

Previous Close:

$22.64

Open:

$22.58

24h Volume:

503.43K

Relative Volume:

0.72

Market Cap:

$733.48M

Revenue:

$796.33M

Net Income/Loss:

$74.95M

P/E Ratio:

11.03

EPS:

2.0427

Net Cash Flow:

$329.83M

1W Performance:

-1.05%

1M Performance:

-17.98%

6M Performance:

-32.24%

1Y Performance:

-34.98%

1-Day Range:

$22.29

$22.91

1-Week Range:

$21.77

$23.69

52-Week Range:

$21.65

$50.79

Collegium Pharmaceutical Inc Stock (COLL) Company Profile

Name

Collegium Pharmaceutical Inc

Sector

Healthcare (1067)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

781-713-3699

Address

100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA

Employee

423

Twitter

Next Earnings Date

2026-11-05

Latest SEC Filings

COLL's Discussions on Twitter

Compare COLL vs TAK, TEVA, HLN, ZTS, VTRS

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
COLL Collegium Pharmaceutical Inc	22.53	733.48M	796.33M	74.95M	329.83M	2.0427
TAK Takeda Pharmaceutical Co Adr	18.86	60.23B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	39.19	45.71B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.26	40.72B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	71.05	29.36B	9.51B	2.64B	2.14B	6.0361
VTRS Viatris Inc	17.83	20.48B	14.57B	-296.50M	1.64B	-0.259

Collegium Pharmaceutical Inc Stock (COLL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-09-25	Initiated	Barclays	Overweight
Jan-10-25	Upgrade	Needham	Hold → Buy
Jul-30-24	Upgrade	H.C. Wainwright	Neutral → Buy
Jun-07-24	Upgrade	Jefferies	Hold → Buy
May-10-24	Downgrade	Needham	Buy → Hold
May-10-24	Downgrade	Piper Sandler	Overweight → Neutral
Jan-04-24	Downgrade	Jefferies	Buy → Hold
Aug-25-23	Reiterated	Needham	Buy
May-02-23	Resumed	Jefferies	Buy
Aug-08-22	Downgrade	H.C. Wainwright	Buy → Neutral
Feb-15-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Aug-06-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-11-21	Reiterated	H.C. Wainwright	Buy
Jul-14-20	Initiated	BWS Financial	Sell
May-27-20	Initiated	Guggenheim	Neutral
Feb-19-20	Resumed	Jefferies	Buy
Oct-30-19	Reiterated	Needham	Buy
May-03-19	Resumed	H.C. Wainwright	Buy
Apr-12-19	Resumed	Janney	Buy
Mar-20-19	Initiated	SunTrust	Hold
Jan-16-19	Reiterated	Needham	Buy
Mar-08-18	Reiterated	H.C. Wainwright	Buy
Feb-07-18	Reiterated	Needham	Buy
Dec-05-17	Reiterated	Needham	Buy
Sep-11-17	Initiated	H.C. Wainwright	Buy
May-11-17	Reiterated	Needham	Buy
Sep-13-16	Initiated	Gabelli & Co	Buy
Jun-01-15	Initiated	Jefferies	Buy
Jun-01-15	Initiated	Needham	Buy
Jun-01-15	Initiated	Piper Jaffray	Overweight

View All

Collegium Pharmaceutical Inc Stock (COLL) Latest News

Sep 24, 2026

Collegium Pharmaceutical Price Target Announced at $50.00/Share by Oppenheimer - Moomoo

Sep 23, 2026

Oppenheimer initiates Collegium Pharmaceutical stock at Outperform By Investing.com - Investing.com South Africa

Sep 23, 2026

Oppenheimer initiates Collegium Pharmaceutical stock at Outperform - Investing.com

Sep 23, 2026

Oppenheimer Initiates Collegium Pharmaceutical at Outperform With $50 Price Target - Yahoo Finance

Sep 23, 2026

Sep 22, 2026

Collegium Pharmaceutical stock holds as market data show no catalyst - AD HOC NEWS

Sep 22, 2026

Sep 19, 2026

Collegium Pharmaceutical stock edges lower as analysts keep Moderate Buy stance - AD HOC NEWS

Sep 19, 2026

Sep 16, 2026

Collegium Pharmaceutical at H.C. Wainwright: pushing beyond pain By Investing.com - Investing.com Nigeria

Sep 16, 2026

Collegium Pharmaceutical at H.C. Wainwright: pushing beyond pain - Investing.com

Sep 16, 2026

Sep 10, 2026

Leerink Partners Initiates Collegium Pharmaceutical(COLL.US) With Buy Rating, Announces Target Price $45 - Moomoo

Sep 10, 2026

(COLL) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Sep 10, 2026

Sep 08, 2026

Collegium to Participate in Upcoming Investor Conferences - GlobeNewswire

Sep 08, 2026

Sep 04, 2026

Collegium Pharmaceutical stock edges higher after recent quarterly update - AD HOC NEWS

Sep 04, 2026

Sep 02, 2026